APOBEC3D and APOBEC3F Potently Promote HIV-1 Diversification and Evolution in Humanized Mouse Model
暂无分享,去创建一个
Kazuyuki Aihara | Shingo Iwami | Junko S. Takeuchi | Yoshio Koyanagi | Kei Sato | K. Aihara | V. Pathak | Wei-Shau Hu | Mamoru Ito | S. Iwami | Y. Koyanagi | D. An | N. Misawa | Kei Sato | J. Takeuchi | Tomoko Kobayashi | A. Takaori-Kondo | Wei-Shau Hu | Vinay K. Pathak | Akifumi Takaori-Kondo | Dong Sung An | Naoko Misawa | Mamoru Ito | Tomoko Kobayashi | Taisuke Izumi | Yuichi Kimura | Taisuke Izumi | Yuichi Kimura
[1] R. König,et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome , 2004, Nature Structural &Molecular Biology.
[2] O. Schwartz,et al. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells , 2010, The Journal of experimental medicine.
[3] C. Cheng‐Mayer,et al. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[4] Mamoru Ito,et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. , 2002, Blood.
[5] Thomas Lengauer,et al. Bioinformatics prediction of HIV coreceptor usage , 2007, Nature Biotechnology.
[6] M. Davenport,et al. APOBEC3G and APOBEC3F rarely co-mutate the same HIV genome , 2012, Retrovirology.
[7] M. Malim,et al. APOBEC3G Inhibits Elongation of HIV-1 Reverse Transcripts , 2008, PLoS pathogens.
[8] J. Thompson,et al. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.
[9] M. Emerman,et al. Ancient Adaptive Evolution of the Primate Antiviral DNA-Editing Enzyme APOBEC3G , 2004, PLoS biology.
[10] Mamoru Ito,et al. A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. , 2011, Blood.
[11] V. Pathak,et al. Distinct Domains within APOBEC3G and APOBEC3F Interact with Separate Regions of Human Immunodeficiency Virus Type 1 Vif , 2008, Journal of Virology.
[12] M. Stenglein,et al. APOBEC3 proteins mediate the clearance of foreign DNA from human cells , 2010, Nature Structural &Molecular Biology.
[13] S. Pillai,et al. Turning up the volume on mutational pressure: Is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3) , 2008, Retrovirology.
[14] J. Garcia,et al. HIV Restriction by APOBEC3 in Humanized Mice , 2013, PLoS pathogens.
[15] A. Meyerhans,et al. Selection, recombination, and G----A hypermutation of human immunodeficiency virus type 1 genomes , 1991, Journal of virology.
[16] Mamoru Ito,et al. Selective infection of CD4+ effector memory T lymphocytes leads to preferential depletion of memory T lymphocytes in R5 HIV-1-infected humanized NOD/SCID/IL-2Rgammanull mice. , 2009, Virology.
[17] M. Malim,et al. Suppression of HIV-1 Infection by APOBEC3 Proteins in Primary Human CD4+ T Cells Is Associated with Inhibition of Processive Reverse Transcription as Well as Excessive Cytidine Deamination , 2012, Journal of Virology.
[18] J. Fellay,et al. Role of retroviral restriction factors in the interferon-α–mediated suppression of HIV-1 in vivo , 2012, Proceedings of the National Academy of Sciences.
[19] Alan S. Perelson,et al. A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo , 2003, Journal of Virology.
[20] Lela Lackey,et al. Human and Rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H Demonstrate a Conserved Capacity To Restrict Vif-Deficient HIV-1 , 2011, Journal of Virology.
[21] J. Goudsmit,et al. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution , 1992, Journal of virology.
[22] R. Harris,et al. Endogenous Origins of HIV-1 G-to-A Hypermutation and Restriction in the Nonpermissive T Cell Line CEM2n , 2012, PLoS pathogens.
[23] J. Fitzgibbon,et al. A new type of G-->A hypermutation affecting human immunodeficiency virus. , 1993, AIDS research and human retroviruses.
[24] Reuben S. Harris,et al. Retroviral restriction by APOBEC proteins , 2004, Nature Reviews Immunology.
[25] W. Brown,et al. APOBEC3F Properties and Hypermutation Preferences Indicate Activity against HIV-1 In Vivo , 2004, Current Biology.
[26] N. A. Temiz,et al. APOBEC3B is an enzymatic source of mutation in breast cancer , 2013, Nature.
[27] M. Malim,et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.
[28] Mamoru Ito,et al. Vpu Augments the Initial Burst Phase of HIV-1 Propagation and Downregulates BST2 and CD4 in Humanized Mice , 2012, Journal of Virology.
[29] N. Kadowaki,et al. APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells , 2012, Scientific Reports.
[30] Ramón Doallo,et al. CircadiOmics: integrating circadian genomics, transcriptomics, proteomics and metabolomics , 2012, Nature Methods.
[31] C. Burant,et al. Molecular cloning of an apolipoprotein B messenger RNA editing protein. , 1993, Science.
[32] F. McCutchan,et al. Human Immunodeficiency Virus Type 1 DNA Sequences Genetically Damaged by Hypermutation Are Often Abundant in Patient Peripheral Blood Mononuclear Cells and May Be Generated during Near-Simultaneous Infection and Activation of CD4+ T Cells , 2001, Journal of Virology.
[33] A. Criscuolo. morePhyML: improving the phylogenetic tree space exploration with PhyML 3. , 2011, Molecular phylogenetics and evolution.
[34] M. Khan,et al. Stably Expressed APOBEC3F Has Negligible Antiviral Activity , 2010, Journal of Virology.
[35] M. Neuberger,et al. DNA deamination in immunity: AID in the context of its APOBEC relatives. , 2007, Advances in immunology.
[36] W. Sugiura,et al. Use of New T-Cell-Based Cell Lines Expressing Two Luciferase Reporters for Accurately Evaluating Susceptibility to Anti-Human Immunodeficiency Virus Type 1 Drugs , 2006, Journal of Clinical Microbiology.
[37] Michel Henry,et al. Sustained G-->A hypermutation during reverse transcription of an entire human immunodeficiency virus type 1 strain Vau group O genome. , 2002, The Journal of general virology.
[38] J. Kappes,et al. Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.
[39] John W. Mellors,et al. Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis , 2005, Journal of Clinical Microbiology.
[40] Mamoru Ito,et al. Dynamics of memory and naïve CD8+ T lymphocytes in humanized NOD/SCID/IL-2Rgammanull mice infected with CCR5-tropic HIV-1. , 2010, Vaccine.
[41] Kaoru Tominaga,et al. Activation of innate immune antiviral response by NOD2 , 2009, Nature Immunology.
[42] B. Blom,et al. Use of a Novel Chimeric Mouse Model with a Functionally Active Human Immune System To Study Human Immunodeficiency Virus Type 1 Infection , 2007, Clinical and Vaccine Immunology.
[43] N. A. Temiz,et al. Evidence for APOBEC3B mutagenesis in multiple human cancers , 2013, Nature Genetics.
[44] Y. Koyanagi,et al. The mouse is out of the bag: insights and perspectives on HIV-1-infected humanized mouse models , 2011, Experimental biology and medicine.
[45] S. Wain-Hobson,et al. Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication , 2006, Nucleic acids research.
[46] Bette Korber,et al. HIV Evolution in Early Infection: Selection Pressures, Patterns of Insertion and Deletion, and the Impact of APOBEC , 2009, PLoS pathogens.
[47] M. Nei,et al. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. , 1993, Molecular biology and evolution.
[48] A. Takaori-Kondo,et al. Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy. , 2008, Mini reviews in medicinal chemistry.
[49] Kazuyuki Aihara,et al. HIV-1 Vpr Accelerates Viral Replication during Acute Infection by Exploitation of Proliferating CD4+ T Cells In Vivo , 2013, PLoS pathogens.
[50] Robert F. Siliciano,et al. Role of APOBEC3G/F-Mediated Hypermutation in the Control of Human Immunodeficiency Virus Type 1 in Elite Suppressors , 2007, Journal of Virology.
[51] R. McClelland,et al. Analysis of the Percentage of Human Immunodeficiency Virus Type 1 Sequences That Are Hypermutated and Markers of Disease Progression in a Longitudinal Cohort, Including One Individual with a Partially Defective Vif , 2009, Journal of Virology.
[52] K. Aihara,et al. Quantification of Deaminase Activity-Dependent and -Independent Restriction of HIV-1 Replication Mediated by APOBEC3F and APOBEC3G through Experimental-Mathematical Investigation , 2014, Journal of Virology.
[53] Yi Zang,et al. Structural basis for hijacking CBF-β and CUL5 E3 ligase complex by HIV-1 Vif , 2014, Nature.
[54] Jianzhi Zhang. Evolution by gene duplication: an update , 2003 .
[55] W. J. Esselman,et al. Identification of APOBEC3DE as Another Antiretroviral Factor from the Human APOBEC Family , 2006, Journal of Virology.
[56] S. Mboup,et al. The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. , 2008, AIDS research and human retroviruses.
[57] Nelson L Michael,et al. Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. , 2008, Virology.
[58] Yuetsu Tanaka,et al. Modulation of Human Immunodeficiency Virus Type 1 Infectivity through Incorporation of Tetraspanin Proteins , 2007, Journal of Virology.
[59] M. Malim,et al. Antiviral Potency of APOBEC Proteins Does Not Correlate with Cytidine Deamination , 2006, Journal of Virology.
[60] V. Pathak,et al. Identification of Two Distinct Human Immunodeficiency Virus Type 1 Vif Determinants Critical for Interactions with Human APOBEC3G and APOBEC3F , 2007, Journal of Virology.
[61] Huldrych F Günthard,et al. 2011 update of the drug resistance mutations in HIV-1. , 2011, Topics in antiviral medicine.
[62] W. Brown,et al. Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus. , 2014, Virology.
[63] M. Malim,et al. Defining APOBEC3 Expression Patterns in Human Tissues and Hematopoietic Cell Subsets , 2009, Journal of Virology.
[64] Mamoru Ito,et al. Remarkable Lethal G-to-A Mutations in vif-Proficient HIV-1 Provirus by Individual APOBEC3 Proteins in Humanized Mice , 2010, Journal of Virology.
[65] W. Greene,et al. Distinct Patterns of Cytokine Regulation of APOBEC3G Expression and Activity in Primary Lymphocytes, Macrophages, and Dendritic Cells* , 2006, Journal of Biological Chemistry.
[66] W. Brown,et al. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction , 2010, Nucleic acids research.
[67] V. Pathak,et al. Likely Role of APOBEC3G-Mediated G-to-A Mutations in HIV-1 Evolution and Drug Resistance , 2009, PLoS pathogens.
[68] V. Pathak,et al. APOBEC3G Restricts HIV-1 to a Greater Extent than APOBEC3F and APOBEC3DE in Human Primary CD4+ T Cells and Macrophages , 2012, Journal of Virology.
[69] M. Si-Tahar,et al. Innate Sensing of HIV-Infected Cells , 2011, PLoS pathogens.
[70] Ariana Harari,et al. Moderate Influence of Human APOBEC3F on HIV-1 Replication in Primary Lymphocytes , 2010, Journal of Virology.
[71] D. Ho,et al. Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification , 2005, PLoS pathogens.
[72] V. Pathak,et al. Identification of Specific Determinants of Human APOBEC3F, APOBEC3C, and APOBEC3DE and African Green Monkey APOBEC3F That Interact with HIV-1 Vif , 2010, Journal of Virology.
[73] M. Nei,et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.
[74] J. Hoxie,et al. Determinant in Human Immunodeficiency Virus Type 1 for Efficient Replication under Cytokine-Induced CD4+ T-Helper 1 (Th1)- and Th2-Type Conditions , 1999, Journal of Virology.
[75] Alan S. Perelson,et al. Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.
[76] M. Kawahara,et al. HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication , 2010, Proceedings of the National Academy of Sciences.
[77] V. Pathak,et al. APOBEC3F and APOBEC3G Inhibit HIV-1 DNA Integration by Different Mechanisms , 2010, Journal of Virology.
[78] S. Conticello. The AID/APOBEC family of nucleic acid mutators , 2008, Genome Biology.
[79] O. Strannegard,et al. Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. , 1991, AIDS research and human retroviruses.
[80] M. Malim,et al. APOBEC3F Can Inhibit the Accumulation of HIV-1 Reverse Transcription Products in the Absence of Hypermutation , 2007, Journal of Biological Chemistry.